Sign In
Buy ASMB
$25.55
+0.330 (+1.31%)
At Close: Jul 24, 2026
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 04'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 07'th May 2021
SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B
Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates
09:47pm, Thursday, 06'th May 2021
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Net Current Asset Value Stocks
12:20pm, Friday, 19'th Mar 2021
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reass
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 05'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript
04:57pm, Sunday, 28'th Feb 2021
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript
Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
06:41am, Friday, 26'th Feb 2021
Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B the
Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates
07:44pm, Thursday, 25'th Feb 2021
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
04:00pm, Thursday, 25'th Feb 2021
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel t
Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know
01:39pm, Wednesday, 24'th Feb 2021
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 05'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences to Wind-Down Microbiome Program
04:02pm, Tuesday, 08'th Dec 2020
Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
08:00am, Tuesday, 17'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two
